Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568905 | 0.84 | TRPV4 (0.53) | KIF11TRPV4GAAKDM4EALDH1A1 | |
| SCHEMBL7569957 | 0.81 | TRPV4 (0.58) | KIF11TRPV4ARSLC22A12CYP3A4 | |
| SCHEMBL8128718 | 0.80 | KIF11 (0.42) | KIF11TRPV4GAAKDM4EALDH1A1 | |
| SCHEMBL5203682 | 0.78 | KIF11 (0.53) | KIF11TRPV4ARSLC22A12 | |
| SCHEMBL30168580 | 0.78 | KIF11 (0.73) | KIF11TRPV4ARSLC22A12CYP3A4 | |
| SCHEMBL1727083 | 0.78 | KIF11 (0.73) | KIF11TRPV4ARSLC22A12CYP3A4 | |
| SCHEMBL8255777 | 0.76 | KIF11 (0.51) | KIF11TRPV4ARPDK2 | |
| SCHEMBL472402 | 0.76 | TRPV4 (0.53) | KIF11TRPV4ARSLC22A12PDK2 | |
| SCHEMBL171819 | 0.76 | KIF11 (0.51) | KIF11TRPV4GAAKDM4EALDH1A1 | |
| SCHEMBL1824261 | 0.76 | KIF11 (0.51) | KIF11TRPV4ARSLC22A12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101565369-B | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL CHEMICAL ENGINEERING CO LTD | 2012-10-03 | — | — | CN | claimed |
| CN-101565369-A | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL (CN) | 2009-10-28 | — | — | CN | claimed |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-25 | — | — | US | disclosed |
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| CN-102245609-B | Can be used as the Imidazopyridazine formonitrile HCN of kinase inhibitor | BRISTOL-MYERS SQUIBB CO. (US) | 2016-03-09 | — | — | CN | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| WO-2010042699-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042699-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| CN-101565369-A | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL (CN) | 2009-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | KIF11 2798/4885TRPV4 3928/4885GAA 2745/4885 |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | KIF11 1862/4885TRPV4 3534/4885GAA 3005/4885 |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | KIF11 3151/4885TRPV4 4323/4885GAA 2457/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | KIF11 3289/4885TRPV4 142/4885GAA 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.